Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.

Annals of hematology - 19 Jan 2026

Robert Florian, Badja Cherif, Boushaki Soraya, Degasperi Andrea, Memari Yasin, Momen Sophie, Roumeliotis Theodoros I, Kozik Zuza, Gozdecka Malgorzata, Choudhary Jyoti, Vassiliou George, Koh Gene Cc, Nik-Zainal Serena

Abstract excerpt

Acute Myeloid Leukemia (AML) remains challenging to treat, especially in cases with mutations in the BCL-6 co-repressor (BCOR), which are associated with poor prognosis and chemo-resistance. In this study, we reveal a synthetic lethal interaction between BCOR and dihydroorotate dehydrogenase (DHODH). We demonstrate that BCOR-deficient cells have a heightened sensitivity to DHODH inhibitors such as brequinar and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biphenyl Compounds
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Oxidoreductases Acting on CH-CH Group Donors

Share to Proto-Oncogene Proteins

Share to Pyrimidines

Share to Reactive Oxygen Species

Share to Repressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41549155
DOI: 10.1007/s00277-026-06773-z
PMCID: PMC12812770

Genes

DHODH
BCOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.PMID 41549155Read ↗

BCOR Mutations Define a Therapeutic Vulnerability to DHODH Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

Heme-Sensing Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-MimeticsSemantic proximity Read ↗

The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid LeukemiaSemantic proximity Read ↗

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukaemiaSemantic proximity Read ↗

The Synergism Between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid LeukemiaSemantic proximity Read ↗

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.Semantic proximity Read ↗

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangementSemantic proximity Read ↗

Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletionSemantic proximity Read ↗

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSemantic proximity Read ↗

Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase MutationsSemantic proximity Read ↗

Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancersSemantic proximity Read ↗

Targeting both the enzymatic and non-enzymatic functions of DHODH as a therapeutic vulnerability in c-Myc-driven cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.